Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation

Trial Profile

Conmana Versus Pemetrexed-based First-line Induction and Maintenance Chemotherapy in Advanced Lung Adenocarcinoma With EGFR-mutation

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 11 Oct 2016

At a glance

  • Drugs Icotinib (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms Convince
  • Sponsors Betta Pharmaceuticals Co Ltd; Zhejiang Beta Pharma
  • Most Recent Events

    • 11 Oct 2016 Primary endpoint (Progression Free Survival) has been met, according to results presented at the 41st European Society for Medical Oncology Congress.
    • 11 Oct 2016 Results assessing efficacy and safety presented at the 41st European Society for Medical Oncology Congress.
    • 29 Sep 2016 Planned End Date changed from 1 Mar 2016 to 1 Dec 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top